Subtypes of White Blood Cells in Patients with Prostate Cancer or Benign Prostatic Hyperplasia and Healthy Individuals

  • Cihan, Yasemin Benderli (Department of Radiation Oncology, Kayseri Education and Research Hospital) ;
  • Arslan, Alaettin (Department of Radiation Oncology, Kayseri Education and Research Hospital) ;
  • Ergul, Mehmet Ali (Department of Urology, Kayseri Education and Research Hospital)
  • Published : 2013.08.30


Background: This study aimed to evaluate the baseline white blood cell (WBC), neutrophil, lymphocyte, monocyte, basophil, eosinophil count, total prostate-specific antigen (TPSA), free PSA (FPSA) level, neutrophilto- lymphocyte and neutrophil-to-monocyte ratios among patients with prostate cancer and benign prostatic hyperplasia (BPH), as well as healthy individuals. Materials and Methods: 2005-2012 laboratory files of 160 patients with prostate cancer at Kayseri Training and Research Hospital, Oncology Outpatient Clinic, 285 patients who were pathologically diagnosed with BPH in Urology Outpatient Clinic and 200 healthy individuals who were admitted to Internal Medicine Outpatient Clinic were retrospectively analyzed. Baseline WBC, neutrophil, lymphocyte, monocyte, basophil, eosinophil count, TPSA, FPSA level, neutrophil-to-lymphocyte ratio and neutrophil-to-monocyte ratio were recorded and compared across groups. Results: Patients with prostate cancer had a lower lymphocyte level compared to the patients with BPH and healthy controls (p<0.001). The mean monocyte count, leukocyte-to-monocyte ratio, and leukocyte-to-lymphocyte ratio were higher in patients with prostate cancer, but without significance. The mean WBC and leukocyte count were lower in patients with prostate cancer, but again without statistical significance (p=0.130). The mean TPSA and FPSA were 39.4 and 5.67, respectively in patients with prostate cancer, while they were 5.78 and 1.28 in patients with BPH. There was a significant difference in the mean TPSA and FPSA levels between the patient groups (p<0.001). Conclusions: Our study results showed that patients with prostate cancer had a lower level of lymphocytes, neutrophils and WBCs and a higher level of monocytes with a significant difference in lymphocyte count, compared to healthy controls. We suggest that lymphocyte count may be used in combination with other parameters in the diagnosis of prostate cancer, thanks to its ease of assessment.


Prostate cancer;benign prostate hyperplasia;white blood cell;neutrophil;monocyte;lymphocyte


  1. Ardies CM (2003). Inflammation as cause for scar cancers of the lung. Integr Cancer Ther, 2, 238-46.
  2. Beer TM, Lalani AS, Lee S, et al (2008). C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer, 112, 2377-83.
  3. Caruso RA, Bellocco R, Pagano M, et al (2002). Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Patho, 15, 831-7.
  4. Cheng I, Witte JS, Jacobsen SJ, et al (2010). Prostatitis, sexually transmitted diseases, and prostate cancer: the California men’s health study. PLoS One, 5, 8736.
  5. Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23
  6. Cho H, Kim JH (2009). Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers, 14, 161-70.
  7. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
  8. Dennis LK, Dawson Dv (2002). Meta-analysis of measures of sexuel activity and prostate cancer. Epidemiology, 13, 72-9.
  9. Fossati G, Ricevuti G, Edwards SW, et al (1999). Neutrophil infiltration into human gliomas. Acta Neuropathol, 98, 349-54.
  10. Fridlender ZG, Albelda SM (2012). Tumor-associated neutrophils: friend or foe? Carcinogenesis, 33, 949-55.
  11. Fujita K, Imamura R, Tanigawa, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer P D, 15, 386-90.
  12. Jensen HK, Donskov F, Marcussen N, et al (2009). Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol, 27, 4709-17.
  13. Jeromino C, Henrique R, Hogue MO, et al (2004). Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res, 10, 4010-4.
  14. Goswami B, Rajappa M, Sharma M, et al (2008). Inflammation: Its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer, 18, 591-9.
  15. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.
  16. Margolis KL, Rodabough RJ, Thomson CA, et al (2007). Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Me, 167, 1837-44.
  17. Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162.
  18. Nakahara Y, Mochiduki Y, Miyamoto Y, et al (2005). Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine needle aspiration biopsy specimen of advanced nonsmall cell lung carcinoma. Cancer, 104, 1271-80.
  19. Nathan C (2006). Neutrophils and immunity: challenges and opportunities. Nat Rev Immuno, 6, 173-82
  20. Nelson JE, Harris RE (2000). Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep, 7, 169-70.
  21. Nonomura N, Takayama H, Kawashima A, et al (2010). Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Sci, 101, 1570-3.
  22. Reid MD, Basturk O, Thirabanjasak D, et al (2011). Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol, 24, 1612-9.
  23. Sfanos KS, De Marzo AM (2012). Prostate cancer and inflammation: the evidence. Histopatholog, 60, 199-215.
  24. Shah R, Mucci NR, Amin A, et al (2001). Postatrohic hiperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J pathol, 158, 1767-73.
  25. Terakawa T, Miyake H, Kanomata N, et al (2008). Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/ml. Urology, 72, 1194-7.
  26. The Committee for Establishment of the Guidelines on Screening for Prostate Cancer, Association JU (2010). Updated Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol, 17, 830-8.
  27. Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4.
  28. Wislez M, Rabbe N, Marchal J, et al (2003). Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res, 63, 1405-12.
  29. Trellakis S, Farjah H, Bruderek K, et al (2011). Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol, 24, 683-93.

Cited by

  1. Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia? vol.15, pp.15, 2014,
  2. Red Cell Distribution Width as a Predictor of Prostate Cancer Progression vol.15, pp.18, 2014,
  3. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men vol.16, pp.14, 2015,
  4. Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line vol.16, pp.1, 2016,
  5. Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study vol.18, pp.12, 2017,
  6. Auswirkungen von definitiver und Salvage-Strahlentherapie auf die Verteilung von Lymphozytensubpopulationen bei Prostatakarzinompatienten vol.193, pp.8, 2017,
  7. The role of blood neutrophil count and the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results pp.1724-6075, 2018,